XT
VRDN icon

XTX Topco’s Viridian Therapeutics VRDN Stock Holding History

XTX Topco’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.05M Buy
275,165
+21,193
+8% +$341K 0.07% 381
2026
Q1 		$4.97M Buy
253,972
+206,939
+440% +$6.15M 0.09% 286
2025
Q4 		$1.46M Buy
+47,033
New +$1.29M 0.04% 759
2025
Q2 		– Sell
-12,197
Closed -$164K – 3233
2025
Q1 		$164K Sell
12,197
-10,775
-47% -$184K 0.01% 1753
2024
Q4 		$440K Buy
+22,972
New +$499K 0.04% 884

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

XTX Topco's VRDN Position: Q2 2026 in Review

XTX Topco increased its Viridian Therapeutics (VRDN) stake by 8.3% in Q2 2026, buying an estimated $341K and bringing the position to 275,165 shares worth $5.05M. The position accounts for 0.07% of the portfolio, ranked #381.

XTX Topco first reported a position in VRDN in Q4 2024 and has held it in 5 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • XTX Topco held 275,165 shares of Viridian Therapeutics worth $5.05M as of Q2 2026.
  • XTX Topco bought 21,193 Viridian Therapeutics shares in Q2 2026, an estimated $341K.
  • Viridian Therapeutics made up 0.07% of XTX Topco's portfolio in Q2 2026, its #381 holding.
  • XTX Topco first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.